Therapeutic efficacy of heparin and direct factor Xa inhibitors in cancer-associated cryptogenic ischemic stroke with venous thromboembolism

Anticoagulation therapy, especially using heparin or recently developed oral direct factor Xa inhibitors (DiXals), is recommended as first-line treatment for cancer-related venous thromboembolism (VTE). However, the preventive efficacy of these anticoagulants for cancer-associated ischemic stroke is still unknown. We retrospectively investigated the efficacy of subcutaneous unfractionated heparin (UFH) and DiXals for preventing the recurrence of cancer-associated cryptogenic ischemic stroke with VTE.

Source: Thrombosis Research - August 23, 2021 Category: Hematology Authors: Genpei Yamaura, Takeshi Ito, Yosuke Miyaji, Naohisa Ueda, Yoshiharu Nakae, Takayuki Momoo, Tatsu Nakano, Yuji Johmura, Yuichi Higashiyama, Hideto Joki, Hiroshi Doi, Hideyuki Takeuchi, Tatsuya Takahashi, Shigeru Koyano, Shigeki Yamaguchi, Mutsumi Yokoyama, Source Type: research